Press Releases
Bexion Pharmaceuticals, Inc. to Present at the 25th Annual Meeting of Future Leaders in the BioTech Industry
FOR IMMEDIATE RELEASE [Covington, KY ~ February 14, 2018] Bexion Pharmaceuticals, Inc., a clinical stage biotechnology company focused on developing innovative cures for cancer, announced that Dr. Ray Takigiku, Founder and CEO of the Company will present an overview and recent advancements of its lead compound, BXQ-350 at the Future Leaders in the BioTech Industry meeting, March 23, 2018 at the NYC Millennium [...]
Bexion Pharmaceuticals Honoree at American Cancer Society Annual Ball
COVINGTON, KY. November 16, 2016 – Bexion Pharmaceuticals was awarded the “Medical Professional Award” at the American Cancer Society’s Annual Striders’ Ball held on November 5, 2016. This is the first time the honor has been bestowed on a company versus an individual medical professional. “We are greatly honored to have been nominated, and to receive this recognition from the American Cancer Society [...]
Bexion Pharmaceuticals Finalist for Cancer Support Community’s Inspiration in Cancer Research Award
COVINGTON, KY. November 8, 2016 – Bexion Pharmaceuticals was honored as a finalists for the “2016 Inspiration in Cancer Research Award” at the Cancer Support Community’s (CSC) annual Evening of Hope Gala, held on October 29, 2016. “The Bexion team is honored to be a finalist for the CSC annual Inspiration Award,” stated Dr. Ray Takigiku, co-founder and CEO of Bexion. “This award [...]
Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute
FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY. September 20, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) and the University of Cincinnati Cancer Institute (UCCI) announced today the dosing of the first patient in the Phase I trial of BXQ-350, a novel anti-cancer therapeutic agent. This open-label trial will include adult patients with advanced solid tumors. The trial is designed to determine the [...]
Bexion Pharmaceuticals and CTI Clinical Trial and Consulting Services Announce Collaboration on First-in-Human Trial Using BXQ-350 for the Treatment of Cancer
FOR IMMEDIATE RELEASE [Cincinnati, OH ~ September 8, 2016] Bexion Pharmaceuticals (Bexion) and CTI Clinical Trial and Consulting Services (CTI) announce their collaboration on the First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. The FDA recently cleared Bexion’s application to initiate the open-label trial that will include adult patients with advanced solid tumors (including glioma, a type of brain [...]
Bexion Pharmaceuticals Receives FDA Clearance For the First Clinical Trial Using BXQ-350 to Dose Patients with Cancer
FOR IMMEDIATE RELEASE Margaret van Gilse 859-757-1652 [email protected] COVINGTON, KY, July 18, 2016- Bexion Pharmaceuticals, LLC (‘Bexion”) announced today that the U.S. Food and Drug Administration (FDA) cleared Bexion’s application to initiate a First-in-Human Phase I clinical trial with BXQ-350 for the treatment of cancer. This open-label trial will include adult patients with advanced solid tumors (including glioma, a type of brain cancer). [...]
